These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34859393)

  • 1. Common Deficiencies Found in the Active Pharmaceutical Ingredient (API) Section of Non-sterile Generic Products Submitted for Registration by SAHPRA.
    Moeti L; Litedu M; Joubert J
    Ther Innov Regul Sci; 2022 Mar; 56(2):276-290. PubMed ID: 34859393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Common deficiencies found in generic Finished Pharmaceutical Product (FPP) applications submitted for registration to the South African Health Products Regulatory Authority (SAHPRA).
    Moeti L; Litedu M; Joubert J
    J Pharm Policy Pract; 2022 Jan; 15(1):6. PubMed ID: 35022074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence Common Deficiencies in Generic Products Submitted for Registration to the South African Health Products Regulatory Authority (SAHPRA).
    Moeti L; Litedu M; Joubert J
    Ther Innov Regul Sci; 2022 Sep; 56(5):822-838. PubMed ID: 35896784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of quality deficiencies found in active pharmaceutical ingredient master files submitted to the WHO Prequalification of Medicines Programme.
    Ortega Diego I; Fake A; Stahl M; Rägo L
    J Pharm Pharm Sci; 2014; 17(2):169-86. PubMed ID: 24934546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory registration timelines of generic medicines in South Africa: Assessment of the performance of SAHPRA between 2011 and 2022.
    Moeti L; Litedu M; Joubert J
    J Pharm Policy Pract; 2023 Mar; 16(1):34. PubMed ID: 36864490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Retrospective Analysis of Applications for Registration of Generic Medicines Processed by the Medicines Control Authority of Zimbabwe.
    Samunda BT; Sithole T; Khoza S
    Ther Innov Regul Sci; 2023 Mar; 57(2):287-294. PubMed ID: 36269550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Implementation of a Risk-Based Assessment Approach by the South African Health Products Regulatory Authority (SAHPRA).
    Moeti L; Litedu M; Joubert J
    Pharmaceut Med; 2023 Jan; 37(1):71-91. PubMed ID: 36598646
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in the utilization of medicines sold in the private sector post- registration in South Africa and the implications for similar countries.
    Mpanza NM; Godman B; Keele MG; Matlala M
    BMC Public Health; 2023 Jan; 23(1):192. PubMed ID: 36709246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. South African Regulatory Authority: The Impact of Reliance on the Review Process Leading to Improved Patient Access.
    Keyter A; Salek S; Danks L; Nkambule P; Semete-Makokotlela B; Walker S
    Front Pharmacol; 2021; 12():699063. PubMed ID: 34366850
    [No Abstract]   [Full Text] [Related]  

  • 10. Common Deficiencies of in vitro Binding Bioequivalence (BE) Studies Submitted in Abbreviated New Drug Applications (ANDAs).
    Lu D; Vivian D; Ren P; Yang Y; Zhang H; Jiang X; Stier E
    AAPS J; 2018 Jan; 20(2):26. PubMed ID: 29327295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Main Reasons for Registration Application Refusal of Generic and Similar Pharmaceutical Drug Products by the Brazilian Health Regulatory Agency (ANVISA).
    do Carmo AC; Piras SS; Rocha NF; Gratieri T
    Biomed Res Int; 2017; 2017():7894937. PubMed ID: 28280742
    [No Abstract]   [Full Text] [Related]  

  • 12. Common chemistry, manufacturing, and control deficiencies in abbreviated new drug applications assessed by the US Food and drug administration: Hurdle to access cost-effective medicines.
    Kulkarni SB; Gaikwad VL
    J Pharmacol Toxicol Methods; 2023; 123():107295. PubMed ID: 37468082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statistics, Quality Review Issues, and Beyond for Generic Drug Applications in Taiwan.
    Chang LC; Gau CS
    Ther Innov Regul Sci; 2013 Nov; 47(6):670-677. PubMed ID: 30235552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Common deficiencies with bioequivalence submissions in abbreviated new drug applications assessed by FDA.
    Liu Q; Davit BM; Cherstniakova SA; Dandamudi S; Walters JF; Lee CH; Raines KW; Ren K; Williamson LN; Conner DP
    AAPS J; 2012 Mar; 14(1):19-22. PubMed ID: 22130775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Common bioanalytical deficiencies with bioequivalence submissions in Abbreviated New Drug Applications.
    Williamson LN; Conner DP; Stier EM; Davit BM
    Bioanalysis; 2014 Feb; 6(4):441-5. PubMed ID: 24568348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of refuse-to-file policy for generic drug application in Taiwan.
    Sun IC; Gau CS
    Regul Toxicol Pharmacol; 2018 Apr; 94():33-39. PubMed ID: 29329941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similarities and Differences of International Practices and Procedures for the Regulation for Active Substance Master Files/Drug Master Files of Human Use: Moving Toward Regulatory Convergence.
    Matsuhama M; Takishita T; Kuribayashi R; Takagi K; Wakao R; Mikami K
    J Pharm Pharm Sci; 2016; 19(2):290-301. PubMed ID: 27518176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the Performance of the South Africa Regulatory Agency: Recommendations for Improved Patients' Access to Medicines.
    Keyter A; Salek S; Gouws J; Banoo S; Walker S
    Ther Innov Regul Sci; 2020 Jul; 54(4):878-887. PubMed ID: 32557310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. WHO Expert Committee on Specifications for Pharmaceutical Preparations. Forty-ninth report.
    World Health Organization
    World Health Organ Tech Rep Ser; 2015; (992):1-210, back cover. PubMed ID: 26118121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmaceutical Industry Evaluation of the Effectiveness and Efficiency of the ZaZiBoNa Collaborative Medicines Registration Initiative: The Way Forward.
    Sithole T; Mahlangu G; Walker S; Salek S
    Front Med (Lausanne); 2022; 9():898725. PubMed ID: 35547215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.